NEW YORK ( TheStreet) -- AtriCure (ATRC - Get Report) was one of several stocks trading near $5 poised to move on above-average volume Tuesday after the company's heart device received regulatory clearance in the U.S.
AtriCure said the Food and Drug Administration gave clearance to its AtriClip system, which is designed to be implanted from the outside of the heart, avoiding contact with circulating blood and eliminating blood flow between the left atrial appendage and the atria.
AtriCure said the initial launch of the AtriClip system in the U.S. is expected to begin later this month with full commercial release planned during the third quarter of 2010.
AtriCure shares jumped by 92 cents, or 17.6%, to $6.15 in the premarket session. The 50-day average daily volume for AtriCure is 27,000, according to the Nasdaq.Elsewhere, Synergetics USA (SURG - Get Report) rose by 18 cents, or 6.6%, to $2.91 in the premarket session after the medical device company posted third-quarter earnings of 13 cents a share, which is up from a profit of 3 cents a share in the year-ago period. The 50-day average daily volume for Synergetics is 135,000.
|More on Biotech 14 Biotech Stocks Facing FDA Approval|